Castle Biosciences, Inc.CSTLNASDAQ
Loading
SG&A Expense Growth Recovery in ProgressRecovering
Percentile Rank39
3Y CAGR-33.1%
5Y CAGR-44.4%
Year-over-Year Change
Year-over-year SG&A expense growth
3Y CAGR
-33.1%/yr
vs +3.4%/yr prior
5Y CAGR
-44.4%/yr
Recent acceleration
Acceleration
-36.4pp
Decelerating
Percentile
P39
Within normal range
vs 5Y Ago
0.1x
Contraction
Streak
1 qtr
Consecutive growthRecovering
| Period | Value |
|---|---|
| Q4 2025 | 1.47% |
| Q3 2025 | -3.72% |
| Q2 2025 | -0.95% |
| Q1 2025 | 17.32% |
| Q4 2024 | -1.06% |
| Q3 2024 | -1.15% |
| Q2 2024 | 5.35% |
| Q1 2024 | 9.99% |
| Q4 2023 | -1.19% |
| Q3 2023 | -0.14% |
| Q2 2023 | -4.45% |
| Q1 2023 | 21.69% |
| Q4 2022 | 4.91% |
| Q3 2022 | -2.33% |
| Q2 2022 | 23.13% |
| Q1 2022 | 21.04% |
| Q4 2021 | 11.35% |
| Q3 2021 | 8.52% |
| Q2 2021 | 14.65% |
| Q1 2021 | 21.41% |
| Q4 2020 | 27.82% |
| Q3 2020 | 12.62% |
| Q2 2020 | -6.19% |
| Q1 2020 | 12.44% |
| Q4 2019 | 38.34% |
| Q3 2019 | 4.41% |
| Q2 2019 | 12.81% |
| Q1 2019 | 45.20% |
| Q4 2018 | 6.28% |
| Q3 2018 | -5.80% |
| Q2 2018 | -1.61% |
| Q1 2018 | 0.00% |